Time to clinical benefit of eplerenone among patients with heart failure and reduced ejection fraction: a subgroups analysis from EMPHASIS-HF trial.

Eplerenone provides statistically significant and clinically meaningful benefits shortly after treatment initiation in most patients, irrespective of clinical profile. This result reinforces the need for an early initiation of eplerenone in HFrEF, as part of rapidly instituting guideline directed medical therapy. This article is protected by copyright. All rights reserved.